Aspectos moleculares de la respuesta antiviral contra el virus de la hepatitis C importantes para el desarrollo de vacunas

Llanes, María Soledad; Palacios, Natalia Soledad; Piccione, Magalí; Ruiz, María Guillermina; Layana, Carla

doi:10.1016/j.eimc.2013.12.012

Cited by 2 publications

(2 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are reports of deaths of children due to liver failure in the past nine years because of acquisition of infection and hepatocellular carcinoma cases are reported in 25 to 27 years after infection (14). It is estimated that the rate of children with chronic hepatitis C will develop cirrhosis is less than 2% (15,16), however there are reports of children requiring liver transplantation (17). The scope of this review is to present a general overview of the current treatments for HCV infection in children.…”

Section: Introductionmentioning

confidence: 99%

Expectations of Treatment of Hepatitis C in Children

Figueroa¹,

Gamboa-Cardeña²,

García‐Mena³

et al. 2016

West Indian Med J

View full text Add to dashboard Cite

Background: HCV infection in children differs from infection in adult through transmission paths, spontaneous viral clearance rate, and fibrosis progression duration of chronic infection. It is estimated that the rate of children with chronic hepatitis C will develop cirrhosis is less than 2%, however there are reports of children requiring liver transplantation. Objective: Was to present a general overview of the current treatments for HCV infection in children. Material and method: Databases such as PubMed, MEDLINE and Scopus were used as information sources to identify and analyzed the current information about the treatment for HCV infection in children. Results: In children the most commonly used drugs are pegylated alpha interferon in combination with ribavirin, both drugs are given in combination therapy in children over 3 years of age with detectable HCV RNA levels. The side effects reported are similar like to adults, including leukopenia, anemia, weight loss (determined by anorexia, nausea, and abdominal pain), changes in behavior, depression, suicidal ideation, thyroid disorders, and transient slowing of the growth rate. Recently, it has been approved that the other drugs with direct antiviral activity (DAAs), the protease inhibitors NS3/4, Boceprevir and Telaprevir were introduced into clinical practice in adults, only Boceprevir was tested and not approved for use in children, (Clinical Trials gob No P07614), adverse effects were reported in 37.5% of participants and included nausea, fatigue, malaise, increased systolic pressure, increased liver enzymes.

show abstract

Section: Introductionmentioning

confidence: 99%

Expectations of Treatment of Hepatitis C in Children

Figueroa¹,

Gamboa-Cardeña²,

García‐Mena³

et al. 2016

West Indian Med J

View full text Add to dashboard Cite

show abstract

“…Genotypes 1, 2 and 3 have worldwide distribution, but their relative prevalence varies from one geographical area to another. 4 The hepatitis C virus can be transmitted by direct, percutaneous, or contaminated blood. Some populations at risk, such as drug users, persons undergoing hemodialysis, transplanted patients, and incarcerated populations present higher prevalence when compared to the general population, due to a higher exposure to the risk factors related to Hepatitis C. 5 The major risk factors for hepatitis C are blood transfusion and blood components from unproven donors to anti-HCV, organ transplants from infected donors, injecting drug use, injectable therapies with contaminated (or unsafe) equipment, hemodialysis; occupational exposure to blood, perinatal transmission, and sexual transmission.…”

Section: Introductionmentioning

confidence: 99%

Hepatitis C and associated risks in prisons: an integrative review Hepatite C e riscos associados em presídios: uma revisão integrativa

Araújo

Pinheiro

Souza

2017

R. pesq. cuid. fundam. online

View full text Add to dashboard Cite

Hepatitis C and associated risks in prisons: an integrative reviewHepatite C e riscos associados em presídios: uma revisão integrativa Hepatitis C y riesgos asociados en las cárceles: una revisión integradora ABSTRACTObjective: To assess the current scientific literature on the prevalence of hepatitis C and associated risks in prisons. Method: This is an integrative review conducted in the Web of Science, Cumulative Index to Nursing and Allied Health Literature (CINAHL) and Literature in the Health Sciences in Latin America and the Caribbean (LILACS in Portuguese) databases, including articles published between 2009 and 2014. Based on the inclusion and exclusion criteria, we selected 16 articles. Results: Descriptive (37.5%) and transverse (50%) articles predominated. All of them had level IV of scientific evidence. The prevalence of Hepatitis C was varied and the main risk factors associated with positive results for hepatitis C were injecting drug use, tattooing and age. Conclusion: Being a long-haul asymptomatic disease, hepatitis C is revealed as a major problem in the prison system, requiring more attention in order to produce knowledge to guide the adoption of effective measures for control and prevention. Descriptors: Hepatitis C; Prevalence; Prisons; Risk factors. (37,5%), transversais (50%). Todos apresentaram nível IV de evidência científica. A prevalência de hepatite C foi variada, e os principais fatores de risco associados à positividade para hepatite C foram o uso de drogas injetáveis, presença de tatuagem, idade. Conclusão: Por ser uma doença de longo curso assintomático, a hepatite C apresenta-se como um problema relevante no sistema prisional, exigindo mais atenção no sentido de produzir conhecimentos, que orientem a adoção de medidas efetivas de controle e prevenção. Descritores: Hepatite C, Prevalência, Prisões, Fatores de risco. La prevalencia de la hepatitis C se varió y los principales factores de riesgo asociados fueron consumo de drogas intravenosas, los tatuajes, la edad. Conclusión: Al ser una enfermedad asintomática de largo recorrido, la hepatitis C se revela como un problema en el sistema penitenciario, lo que requiere más atención con el fin de producir conocimiento para guiar la adopción de medidas eficaces de control y prevención.

show abstract

Aspectos moleculares de la respuesta antiviral contra el virus de la hepatitis C importantes para el desarrollo de vacunas

Cited by 2 publications

References 63 publications

Expectations of Treatment of Hepatitis C in Children

Expectations of Treatment of Hepatitis C in Children

Hepatitis C and associated risks in prisons: an integrative review Hepatite C e riscos associados em presídios: uma revisão integrativa

Contact Info

Product

Resources

About